{"pmid":32400359,"title":"Coronavirus disease (COVID-19) - impact on vaccine preventable diseases.","text":["Coronavirus disease (COVID-19) - impact on vaccine preventable diseases.","Euro Surveill","Hungerford, Daniel","Cunliffe, Nigel A","32400359"],"journal":"Euro Surveill","authors":["Hungerford, Daniel","Cunliffe, Nigel A"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32400359","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.2807/1560-7917.ES.2020.25.18.2000756","keywords":["covid-19","immunisation","outbreak","surveillance","vaccine","vaccine-preventable diseases"],"link_comment_for":"32347202","topics":["Prevention"],"weight":1,"_version_":1666865855034556416,"score":9.490897,"similar":[{"pmid":32287038,"pmcid":"PMC7164788","title":"A Case for Participatory Disease Surveillance of the COVID-19 Pandemic in India.","text":["A Case for Participatory Disease Surveillance of the COVID-19 Pandemic in India.","The coronavirus disease pandemic requires the deployment of novel surveillance strategies to curtail further spread of the disease in the community. Participatory disease surveillance mechanisms have already been adopted in countries for the current pandemic. India, with scarce resources, good telecom support, and a not-so-robust heath care system, makes a strong case for introducing participatory disease surveillance for the prevention and control of the pandemic. India has just launched Aarogya Setu, which is a first-of-its-kind participatory disease surveillance initiative in India. This will supplement the existing Integrated Disease Surveillance Programme in India by finding missing cases and having faster aggregation, analysis of data, and prompt response measures. This newly created platform empowers communities with the right information and guidance, enabling protection from infection and reducing unnecessary contact with the overburdened health care system. However, caution needs to be exercised to address participation from digitally isolated populations, ensure the reliability of data, and consider ethical concerns such as maintaining individual privacy.","JMIR Public Health Surveill","Garg, Suneela","Bhatnagar, Nidhi","Gangadharan, Navya","32287038"],"abstract":["The coronavirus disease pandemic requires the deployment of novel surveillance strategies to curtail further spread of the disease in the community. Participatory disease surveillance mechanisms have already been adopted in countries for the current pandemic. India, with scarce resources, good telecom support, and a not-so-robust heath care system, makes a strong case for introducing participatory disease surveillance for the prevention and control of the pandemic. India has just launched Aarogya Setu, which is a first-of-its-kind participatory disease surveillance initiative in India. This will supplement the existing Integrated Disease Surveillance Programme in India by finding missing cases and having faster aggregation, analysis of data, and prompt response measures. This newly created platform empowers communities with the right information and guidance, enabling protection from infection and reducing unnecessary contact with the overburdened health care system. However, caution needs to be exercised to address participation from digitally isolated populations, ensure the reliability of data, and consider ethical concerns such as maintaining individual privacy."],"journal":"JMIR Public Health Surveill","authors":["Garg, Suneela","Bhatnagar, Nidhi","Gangadharan, Navya"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32287038","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.2196/18795","keywords":["covid-19","india","infectious disease","outbreak","pandemic","participatory","public health","surveillance"],"locations":["India","India","India","India","India"],"countries":["India"],"countries_codes":["IND|India"],"topics":["Prevention"],"weight":1,"_version_":1666138491393671168,"score":64.176865},{"pmid":32110875,"pmcid":"PMC7141113","title":"Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","text":["Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.","J Clin Med","Pang, Junxiong","Wang, Min Xian","Ang, Ian Yi Han","Tan, Sharon Hui Xuan","Lewis, Ruth Frances","Chen, Jacinta I-Pei","Gutierrez, Ramona A","Gwee, Sylvia Xiao Wei","Chua, Pearleen Ee Yong","Yang, Qian","Ng, Xian Yi","Yap, Rowena Ks","Tan, Hao Yi","Teo, Yik Ying","Tan, Chorh Chuan","Cook, Alex R","Yap, Jason Chin-Huat","Hsu, Li Yang","32110875"],"abstract":["Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence."],"journal":"J Clin Med","authors":["Pang, Junxiong","Wang, Min Xian","Ang, Ian Yi Han","Tan, Sharon Hui Xuan","Lewis, Ruth Frances","Chen, Jacinta I-Pei","Gutierrez, Ramona A","Gwee, Sylvia Xiao Wei","Chua, Pearleen Ee Yong","Yang, Qian","Ng, Xian Yi","Yap, Rowena Ks","Tan, Hao Yi","Teo, Yik Ying","Tan, Chorh Chuan","Cook, Alex R","Yap, Jason Chin-Huat","Hsu, Li Yang"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32110875","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.3390/jcm9030623","keywords":["mers-cov","sars-cov","diagnostics","global health","novel coronavirus","outbreak","treatments","vaccine"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138492860628992,"score":63.315105},{"pmid":32238336,"pmcid":"PMC7124951","title":"Global Telemedicine Implementation and Integration Within Health Systems to Fight the COVID-19 Pandemic: A Call to Action.","text":["Global Telemedicine Implementation and Integration Within Health Systems to Fight the COVID-19 Pandemic: A Call to Action.","On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) outbreak as a pandemic, with over 720,000 cases reported in more than 203 countries as of 31 March. The response strategy included early diagnosis, patient isolation, symptomatic monitoring of contacts as well as suspected and confirmed cases, and public health quarantine. In this context, telemedicine, particularly video consultations, has been promoted and scaled up to reduce the risk of transmission, especially in the United Kingdom and the United States of America. Based on a literature review, the first conceptual framework for telemedicine implementation during outbreaks was published in 2015. An updated framework for telemedicine in the COVID-19 pandemic has been defined. This framework could be applied at a large scale to improve the national public health response. Most countries, however, lack a regulatory framework to authorize, integrate, and reimburse telemedicine services, including in emergency and outbreak situations. In this context, Italy does not include telemedicine in the essential levels of care granted to all citizens within the National Health Service, while France authorized, reimbursed, and actively promoted the use of telemedicine. Several challenges remain for the global use and integration of telemedicine into the public health response to COVID-19 and future outbreaks. All stakeholders are encouraged to address the challenges and collaborate to promote the safe and evidence-based use of telemedicine during the current pandemic and future outbreaks. For countries without integrated telemedicine in their national health care system, the COVID-19 pandemic is a call to adopt the necessary regulatory frameworks for supporting wide adoption of telemedicine.","JMIR Public Health Surveill","Ohannessian, Robin","Duong, Tu Anh","Odone, Anna","32238336"],"abstract":["On March 11, 2020, the World Health Organization declared the coronavirus disease 2019 (COVID-19) outbreak as a pandemic, with over 720,000 cases reported in more than 203 countries as of 31 March. The response strategy included early diagnosis, patient isolation, symptomatic monitoring of contacts as well as suspected and confirmed cases, and public health quarantine. In this context, telemedicine, particularly video consultations, has been promoted and scaled up to reduce the risk of transmission, especially in the United Kingdom and the United States of America. Based on a literature review, the first conceptual framework for telemedicine implementation during outbreaks was published in 2015. An updated framework for telemedicine in the COVID-19 pandemic has been defined. This framework could be applied at a large scale to improve the national public health response. Most countries, however, lack a regulatory framework to authorize, integrate, and reimburse telemedicine services, including in emergency and outbreak situations. In this context, Italy does not include telemedicine in the essential levels of care granted to all citizens within the National Health Service, while France authorized, reimbursed, and actively promoted the use of telemedicine. Several challenges remain for the global use and integration of telemedicine into the public health response to COVID-19 and future outbreaks. All stakeholders are encouraged to address the challenges and collaborate to promote the safe and evidence-based use of telemedicine during the current pandemic and future outbreaks. For countries without integrated telemedicine in their national health care system, the COVID-19 pandemic is a call to adopt the necessary regulatory frameworks for supporting wide adoption of telemedicine."],"journal":"JMIR Public Health Surveill","authors":["Ohannessian, Robin","Duong, Tu Anh","Odone, Anna"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238336","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.2196/18810","keywords":["covid-19","sars-cov-2","coronavirus","digital health","digital medicine","outbreak","pandemic","public health","surveillance","telehealth","telemedicine"],"locations":["United Kingdom","Italy","France"],"countries":["United Kingdom","France","Italy"],"countries_codes":["GBR|United Kingdom","FRA|France","ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138490348240898,"score":56.157322},{"pmid":32328406,"pmcid":"PMC7177048","title":"Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.","text":["Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.","The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and its impact on global health have made imperative the development of effective and safe vaccines for this lethal strain. SARS-CoV-2 now adds to the list of coronavirus diseases that have threatened global health, along with the SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) coronaviruses that emerged in 2002/2003 and 2012, respectively. As of April 2020, no vaccine is commercially available for these coronavirus strains. Nevertheless, the knowledge obtained from the vaccine development efforts for MERS and SARS can be of high value for COVID-19 (coronavirus disease 2019). Here, we review the past and ongoing vaccine development efforts for clinically relevant coronavirus strains with the intention that this information helps in the development of effective and safe vaccines for COVID-19. In addition, information from naturally exposed individuals and animal models to coronavirus strains is described for the same purpose of helping into the development of effective vaccines against COVID-19.","Infect Dis Ther","Padron-Regalado, Eriko","32328406"],"abstract":["The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and its impact on global health have made imperative the development of effective and safe vaccines for this lethal strain. SARS-CoV-2 now adds to the list of coronavirus diseases that have threatened global health, along with the SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) coronaviruses that emerged in 2002/2003 and 2012, respectively. As of April 2020, no vaccine is commercially available for these coronavirus strains. Nevertheless, the knowledge obtained from the vaccine development efforts for MERS and SARS can be of high value for COVID-19 (coronavirus disease 2019). Here, we review the past and ongoing vaccine development efforts for clinically relevant coronavirus strains with the intention that this information helps in the development of effective and safe vaccines for COVID-19. In addition, information from naturally exposed individuals and animal models to coronavirus strains is described for the same purpose of helping into the development of effective vaccines against COVID-19."],"journal":"Infect Dis Ther","authors":["Padron-Regalado, Eriko"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328406","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s40121-020-00300-x","keywords":["covid-19","coronavirus","mers","sars","vaccine"],"topics":["Treatment"],"weight":1,"_version_":1666138494558273536,"score":49.00402},{"pmid":32495979,"title":"Emergence of novel coronavirus and progress toward treatment and vaccine.","text":["Emergence of novel coronavirus and progress toward treatment and vaccine.","In late December 2019, a group of patients was observed with pneumonia-like symptoms that were linked with a wet market in Wuhan, China. The patients were found to have a novel coronavirus genetically related to a bat coronavirus that was termed SARS-CoV-2. The virus gradually spread worldwide and was declared a pandemic by WHO. Scientists have started trials on potential preventive and treatment options. Currently, there is no specific approved treatment for SARS-CoV-2, and various clinical trials are underway to explore better treatments. Some previously approved antiviral and other drugs have shown some in vitro activity. Here we summarize the fight against this novel coronavirus with particular focus on the different treatment options and clinical trials exploring treatment as well as work done toward development of vaccines.","Rev Med Virol","Khan, Muhammad Muzamil","Noor, Amna","Madni, Asadullah","Shafiq, Mudassir","32495979"],"abstract":["In late December 2019, a group of patients was observed with pneumonia-like symptoms that were linked with a wet market in Wuhan, China. The patients were found to have a novel coronavirus genetically related to a bat coronavirus that was termed SARS-CoV-2. The virus gradually spread worldwide and was declared a pandemic by WHO. Scientists have started trials on potential preventive and treatment options. Currently, there is no specific approved treatment for SARS-CoV-2, and various clinical trials are underway to explore better treatments. Some previously approved antiviral and other drugs have shown some in vitro activity. Here we summarize the fight against this novel coronavirus with particular focus on the different treatment options and clinical trials exploring treatment as well as work done toward development of vaccines."],"journal":"Rev Med Virol","authors":["Khan, Muhammad Muzamil","Noor, Amna","Madni, Asadullah","Shafiq, Mudassir"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32495979","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/rmv.2116","keywords":["sars-cov-2","bat coronavirus","chloroquine","remdesivir","vaccine"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1668712823893524480,"score":48.28713}]}